- Research
IGTP researchers confirm the feasibility of immunotherapy in cells of the immune system of patients with type 1 diabetes
Researchers from the Immunology of Diabetes research group of the Germans Trias i Pujol Research Institute (IGTP) have confirmed, in human cells, that liposomes designed as immunotherapy for type 1 diabetes (T1D) are a valid strategy to arrest the autoimmune attack characteristic of this disease. They have done so in a preclinical study demonstrating the tolerogenic effect of these liposomes on cells of the immune system of patients with T1D. The results have been published in the journal Frontiers in Immunology.
